Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...

Pfizer said on Thursday it will end global development of its hemophilia gene therapy, Beqvez, citing soft demand from ...

Less than a year after approval, Pfizer said it plans to discontinue its hemophilia B gene therapy fidanacogene elaparvovec ...

Pfizer may appeal to income investors, but growth prospects remain uncertain. Read why PFE stock might struggle to gain ...

PFE offers a 6.73% dividend yield and growth potential, driven by strategic acquisitions, R&D, and discounted valuations.

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and ...

Pfizer CEO Dr. Albert Bourla was loudly booed during a White House Black History Month event where he was introduced by President Trump.

We can refer to full-year 2019 revenue of about $51 billion and the company's comments about potential revenue of more than ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

Pfizer Inc. (NYSE:PFE – Get Free Report) was the target of some unusual options trading activity on Friday. Stock traders ...